Bayer AG will not attempt to renew its CE mark for the Essure permanent birth control method, ending the product's use in EU and other countries outside the US, the firm said Sept. 18. Bayer says there is "not much patient interest" in Essure in Europe.
Meanwhile, US FDA still supports uses of the product by American women, albeit with a black-box on the label with a checklist of safety warnings that obstetrical and gynecological providers...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?